Trial Profile
A Phase II Study of Perioperative mFOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach (MISP #52216)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 18 May 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2025.
- 18 May 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2024.
- 18 May 2023 Status changed from recruiting to active, no longer recruiting.